Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy

Annual Review of Medicine

Volumn 68, Issue , 2017, Pages 183-196

  Jones, Robert P ^a,b   Poston, Graeme J ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal liver metastases; Induction; Neoadjuvant; Surgery

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL PRACTICE; COLORECTAL LIVER METASTASIS; HUMAN; LIVER RESECTION; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; ADJUVANT CHEMOTHERAPY; CLINICAL DECISION MAKING; COLORECTAL TUMOR; GENETICS; LIVER TUMOR; METASTASIS RESECTION; PATHOLOGY; PATIENT SELECTION; SECONDARY; TREATMENT CONTRAINDICATION;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL DECISION-MAKING; COLORECTAL NEOPLASMS; CONTRAINDICATIONS, PROCEDURE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; METASTASECTOMY; PATIENT SELECTION; PERIOPERATIVE CARE;

EID: 85009989754     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-062415-093510     Document Type: Article

References (65)

1. Jones RP, Jackson R, Dunne DF, et al. 2012. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br. J. Surg. 99(4):477-86
2. Taylor A, Primrose LW, Kelsh MF, et al. 2012. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin. Epidemiol. 4:283-301
3. Jones RP, Vauthey J-N, Adam R, et al. 2012. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br. J. Surg. 99(9):1263-69
4. Adam R, De Gramont A, Figueras J, et al. 2012. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17(10):1225-39
5. Garden OJ, Rees M, Poston GJ, et al. 2006. Guidelines for resection of colorectal cancer liver metastases. Gut 55(Suppl. 3):31-8
6. Wicherts DA, Miller R, de Haas RJ, et al. 2008. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann. Surg. 248(6):994-1005
7. Schnitzbauer AA, Lang SA, Goessmann H, et al. 2012. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann. Surg. 255(3):405-14
8. Fong Y, Fortner J, Sun RL, et al. 1999. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230(3):309-18
9. Rees M, Tekkis PP, Welsh FKS, et al. 2008. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann. Surg. 247(1):125-35
10. Nordlinger B, Guiguet M, Vaillant JC, et al. 1996. Surgical resection of colorectal carcinomametastases to the liver. Aprognostic scoring system to improve case selection, based on 1568 patients. Cancer 77(7):1254-62
11. Zakaria S, Donohue JH, Que FG, et al. 2007. Hepatic resection for colorectal metastases: value for risk scoring systems Ann. Surg. 246(2):183-91
12. Roberts KJ, White A, Cockbain A, et al. 2014. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br. J. Surg. 101(7):856-66
13. Schreckenbach T, Malkomes P, Bechstein WO, et al. 2015. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg. Today 45(12):1527-34
14. Blazer DG, Kishi Y, Maru DM, et al. 2008. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J. Clin. Oncol. 26(33):5344-51
15. Andreou A, Kopetz S, Maru DM, et al. 2012. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann. Surg. 256(4):642-50
16. Margonis GA, Spolverato G, Kim Y, et al. 2015. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann. Surg. Oncol. 22(13):4158-65
17. Margonis GA, Kim Y, Spolverato G, et al. 2015. Association between specific mutations in KRAS Codon 12 And Colorectal Liver Metastasis. JAMA Surg. 150(8):722-29
18. Løes IM, Immervoll H, Sorbye H, et al. 2016. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int. J. Cancer 139(3):647-56
19. Balachandran VP, Arora A, Gonen M, et al. 2016. A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases. Clin. Cancer Res. 15(22):2575-82
20. National Comprehensive Cancer Network (NCCN). 2012. Clinical Practice Guidelines in Oncology; Colon Cancer v. 3. https://www. nccn. org/professionals/physician-gls/f-guidelines. asp#site
21. Poston GJ, Tait D, O'Connell S, et al. 2011. Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 343:d6751
22. PortierG, Elias D, Bouche O, et al. 2006. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J. Clin. Oncol. 24(31):4976-82
23. Mitry E, Fields ALA, Bleiberg H, et al. 2008. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J. Clin. Oncol. 26(30):4906-11
24. André T, Boni C, Navarro M, et al. 2009. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19):3109-16
25. Van CE, Labianca R, Bodoky G, et al. 2009. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27(19):3117-25
26. Ychou M, Hohenberger W, Thezenas S, et al. 2009. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 20(12):1964-70
27. Morris EJA, Forman D, Thomas JD, et al. 2010. Surgical management and outcomes of colorectal cancer liver metastases. Brit. J. Surg. 97(7):1110-18
28. Nordlinger B, Sorbye H, Glimelius B, et al. 2008. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007-16
29. Nordlinger B, Sorbye H, Glimelius B, et al. 2013. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14(12):1208-15
30. Sorbye H, Mauer M, Gruenberger T, et al. 2012. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg. 255(3):534-39
31. Adam R, Bhangui P, Poston G, et al. 2010. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases Ann. Surg. 252(5):774-87
32. Ayez N, van der Stok EP, Grunhagen DJ, et al. 2015. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur. J. Surg. Oncol. 41(7):859-67
33. Primrose J, Falk S, Finch-Jones M, et al. 2014. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 15(6):601-11
34. Nordlinger B, Poston GJ, Goldberg RM. 2014. Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver J. Clin. Oncol. 33(3):241-43
35. Nordlinger B, Van Cutsem E, GruenbergerT, et al. 2009.combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20(6):985-92
36. Adam R, de Gramont A, Figueras J, et al. 2015. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat. Rev. 41(9):729-41
37. Pritchard CC, Grady WM. 2011. Colorectal cancer molecular biology moves into clinical practice. Gut 60(1):116-29
38. Hutchins G, Southward K, Handley K, et al. 2011. Value ofmismatch repair, KRAS, and BRAFmutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29(10):1261-70
39. RoockWD, Claes B, Bernasconi D, et al. 2010. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8):753-62
40. Rosmarin D, Palles C, Church D, et al. 2014. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32(10):1031-39
41. Jones OM, Rees M, John TG, et al. 2005. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br. J. Surg. 92(9):1165-68
42. Vakiani E, Janakiraman M, Shen R, et al. 2012.comparative genomic analysis of primary versusmetastatic colorectal carcinomas. J. Clin. Oncol. 30(24):2956-62
43. Gerlinger M, Rowan AJ, Horswell S, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10):883-92
44. Adam R, Avisar E, Ariche A, et al. 2001. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol. 8(4):347-53
45. Folprecht G, Grothey A, Alberts S, et al. 2005. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16(8):1311-19
46. Jones RP, Hamann S, Malik HZ, et al. 2014. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur. J. Cancer 50(9):1590-601
47. Falcone A, Ricci S, Brunetti I, et al. 2007. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol. 25(13):1670-76
48. Van CE, Köhne C-H, Láng I, et al. 2011. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15):2011-19
49. Bokemeyer C, Bondarenko I, Makhson A, et al. 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5):663-71
50. Bokemeyer C, Bondarenko I, Hartmann JT, et al. 2011. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 22(7):1535-46
51. Garufi C, Torsello A, Tumolo S, et al. 2010. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br. J. Cancer 103(10):1542-47
52. UK National Institute for Healthcare and Clinical Excellence. 2010. Guidance TA176. https://www. nice. org. uk/guidance/ta176/documents/ta176-colorectal-cancer-first-line-cetuximab-appendix-bproposal-paper-presented-to-the-institutes-guidance-executive2
53. Loupakis F, Cremolini C, Masi G, et al. 2014. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371(17):1609-18
54. D'Angelica MI, Correa-Gallego C, Paty PB, et al. 2015. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann. Surg. 261(2):353-60
55. Allen PJ, Nissan A, Picon AI, et al. 2005. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J. Am. Coll. Surg. 201(1):57-65
56. Allard MA, Sebagh M, Baillie G, et al. 2015.comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann. Surg. Oncol. 22(6):1925-32
57. Vauthey J-N, Pawlik TM, Ribero D, et al. 2006. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24(13):2065-72
58. Martin RCG, Scoggins CR, Schreeder M, et al. 2015. Randomized controlled trial of irinotecan drugeluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 121(20):3649-58
59. Jones RP, Malik HZ, Fenwick SW, et al. 2015. Interim follow up results from a phase II study of neoadjuvant chemoembolization of resectable colorectal liver metastases (CRLM) with transcatheter hepatic therapy with irinotecan-eluting beads. ASCO Annu. Meet. Proc. Abstr. 3588
60. FolprechtG, Gruenberger T, BechsteinWO, et al. 2010. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 11(1):38-47
61. Choti MA, Thomas M, Wong SL, et al. 2015. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann. Surg. Oncol. 23(2):375-81
62. Ruers T, Punt C, Van CF, et al. 2012. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomizedEORTC Intergroup phase II study (EORTC 40004). Ann. Oncol. 23(10):2619-26
63. Ruers T, Punt CJA, van CF, et al. 2015. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomised phase II study of the EORT65C-NCRI CCSG-ALM Intergroup 40004 (CLOCC). Ann. Oncol. 26(Suppl. 4):iv114-iv115
64. Van CE, Köhne C-H, Hitre E, et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14):1408-17
65. HeinemannV, von Weikersthal LF, Decker T, et al. 2014. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15(10):1065-75